291 related articles for article (PubMed ID: 17219340)
1. [Effect of candesartan cilexetil with hydrochlorothiazide on blood pressure and ST-segment depression in patients with arterial hypertension].
Uen S; Un I; Fimmers R; Vetter H; Mengden T
Dtsch Med Wochenschr; 2007 Jan; 132(3):81-6. PubMed ID: 17219340
[TBL] [Abstract][Full Text] [Related]
2. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Weisser B; Gerwe M; Braun M; Funken C
Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
4. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ].
Bramlage P; Schönrock E; Odoj P; Wolf WP; Funken C
MMW Fortschr Med; 2008 Jan; 149 Suppl 4():172-81. PubMed ID: 18402243
[TBL] [Abstract][Full Text] [Related]
5. Management of patients with uncontrolled arterial hypertension--the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZ.
Mengden T; Vetter H; Tousset E; Uen S
BMC Cardiovasc Disord; 2006 Aug; 6():36. PubMed ID: 16942618
[TBL] [Abstract][Full Text] [Related]
6. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension.
Bönner G; Fuchs W
Curr Med Res Opin; 2004 May; 20(5):597-602. PubMed ID: 15140325
[TBL] [Abstract][Full Text] [Related]
7. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
Asmar R; Porcellati C; Dusing R
Drugs Exp Clin Res; 2004; 30(4):153-61. PubMed ID: 15553661
[TBL] [Abstract][Full Text] [Related]
8. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
[TBL] [Abstract][Full Text] [Related]
9. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
Fogari R; Mugellini A; Derosa G;
J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):139-44. PubMed ID: 17907102
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care.
Edes I;
Clin Drug Investig; 2009; 29(5):293-304. PubMed ID: 19366271
[TBL] [Abstract][Full Text] [Related]
12. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
13. Candesartan cilexetil effectively reduces blood pressure in hypertensive children.
Franks AM; O'Brien CE; Stowe CD; Wells TG; Gardner SF
Ann Pharmacother; 2008 Oct; 42(10):1388-95. PubMed ID: 18664605
[TBL] [Abstract][Full Text] [Related]
14. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.
Lee HY; Hong BK; Chung WJ; Lee BK; Lee SH; Jeon DW; Ahn YK; Kim D; Park CK; Kim SH; Jung HO; Kim BO; Choi D
Clin Ther; 2011 Aug; 33(8):1043-56. PubMed ID: 21831438
[TBL] [Abstract][Full Text] [Related]
15. Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.
Oparil S
Am J Cardiol; 1999 Nov; 84(10A):35S-41S. PubMed ID: 10588093
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide.
Neldam S; Forsén B;
Drugs Aging; 2001; 18(3):225-32. PubMed ID: 11302289
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
Brunner HR; Arakawa K
Clin Drug Investig; 2006; 26(4):185-93. PubMed ID: 17163250
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of candesartan and candesartan/HCT fixed dose combination in patients with hypertension.
Setiawati A; Pohan T
Acta Med Indones; 2013 Jul; 45(3):193-201. PubMed ID: 24045389
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension--comparison with a combination of losartan and hydrochlorothiazide.
Ohma KP; Milon H; Valnes K
Blood Press; 2000; 9(4):214-20. PubMed ID: 11055474
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
